Bio-Rad launches anti-pertuzumab antibodies

1-Feb-2022

Pertuzumab is a targeted cancer drug that binds to the HER2 protein, which is overexpressed in HER2-positive cancers, preventing cell growth and proliferation

Bio-Rad Laboratories, a supplier of research and clinical diagnostic products, has introduced four inhibitory antibodies highly specific to pertuzumab (Perjeta). These ready-made antibodies inhibit the binding of the drug to its target, human epidermal growth factor 2 (HER2), and are designed to help researchers to develop selective and sensitive assays for bioanalysis and drug monitoring of pertuzumab and its biosimilars.

Pertuzumab is a targeted cancer drug that binds to the HER2 protein, which is overexpressed in HER2-positive cancers, preventing cell growth and proliferation. The range of anti-pertuzumab antibodies includes monovalent Fab format antibodies suitable for the development of a pharmacokinetic bridging ELISA to measure free drug, as well as fully human IgG1 antibodies with varying levels of affinity, which can be used as a surrogate positive control or reference standard in an anti-drug antibody assay.

“We’re continuously introducing new ranges of recombinant, monoclonal anti-idiotypic antibodies to support researchers in developing robust methods that deliver reproducible and translatable results,” said Amanda Turner, Bio-Rad Product Manager, Life Science Group. “These sequence-defined reagents are well-characterised and non-animal-derived to ensure batch-to batch consistency and help reduce the use of animals in scientific research.”

The antibodies are generated using the human combinatorial antibody libraries (HuCAL) and CysDisplay, a proprietary method of phage display, along with guided selection methods to obtain targeted reagents. The recombinant production method is used to ensure consistent and secure supply.

Sign up for your free email newsletter

The anti-pertuzumab antibodies are approved for in vitro research purposes and for commercial services providing in vitro testing to support preclinical and clinical drug development.

Companies